⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

March 25, 2026Kidney International ReportsOpen Access

Wcn26-7734 Dosing, Treatment Patterns, Uacr Changes, and Safety With Finerenone Treatment: An Interim Analysis of the Asia-Pacific Cohort of Fine-Real

Nan Hee Kim Lei Guo Kevin M. Pantalone Christoph Wanner David C. Wheeler Nihar R. Desai Ricardo Correa-Rotter Susanne B. Nicholas Sonia Ares Gómez Andrea Horvat-Broecker Marcel Schulze Martin Merz Sankar D. Navaneethan

View Full Paper

Ask AI

Bookmark

Share

Key Points

To assess the impact of finerenone treatment on renal function and safety in patients with diabetic nephropathy.
Analyzed kidney function using eGFR and UACR.
Categorized patients based on biopsy results as diabetic nephropathy (DN) or non-diabetic renal disease (NDRD).
Monitored follow-up data from SGLT2i initiation up to 60 months.
Among 67 included patients, 31 (46%) had DN and 36 (54%) had NDRD.
DN patients showed significantly more renal structural changes compared to NDRD patients.
SGLT2i therapy resulted in a slower eGFR decline compared to untreated patients, particularly beneficial in DN cases.

Implication

Interim analysis demonstrates slower eGFR decline in diabetic nephropathy with SGLT2i treatment, indicating potential long-term benefits.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Kim et al. (2026) studied this question.

synapsesocial.com/papers/69c770418bbfbc51511e06c4 https://doi.org/10.1016/j.ekir.2026.104643

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1#1626 The role of sodium-glucose cotransporter 2 inhibitors in diabetic nephropathy and non diabetic renal disease in diabetes mellitus type 2 patients2024
2Association of SGLT2 inhibitors and GLP-1 receptor agonists with mortality and renal outcomes in patients with diabetes and chronic kidney disease: the diabetic nephropathy management and outcome (DINAMO) studyCohort Study · 2026
31847-P: SGLT2 Inhibitor Attenuates eGFR Slope in Type 2 Diabetes with UACR &lt;30 mg/gCrHuman Clinical Trial · 2026
4#3115 Effectiveness of SGLT2 inhibitors in patients with glomerulonephritis: a single center experience2024
5Early reduction in albuminuria is associated with a steeper ‘dip’ in initial <scp>estimated glomerular filtration rate</scp> but favourable long‐term kidney outcomes in people with diabetes receiving <scp>sodium‐glucose cotransporter‐2</scp> inhibitors2024 · 4 citations

More related papers

Impact of sodium–glucose cotransporter 2 inhibitors on renal function in participants with type 2 diabetes and chronic kidney disease with normoalbuminuria2020
Divergent renal benefits of SGLT2 inhibitors and mineralocorticoid receptor antagonists in non-diabetic kidney disease2026
#1549 The effect of sglt2 inhibitors (dapaglifozin) on albuminuria in patients of diabetic nephropathy above standard of care2024

More from Kidney International Reports

From Molecular Signal to Clinical Action in Cardiovascular-Kidney-Metabolic DiseaseTue,
Perioperative Risk Assessment and Management in Patients with Chronic Kidney Disease, Dialysis Dependence, and Kidney TransplantationThu,